GSA Capital Partners LLP Cuts Stake in Neumora Therapeutics

Hedge fund reduces position in biotech company by 88% in Q3

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

According to a recent SEC filing, GSA Capital Partners LLP significantly reduced its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) during the third quarter of 2026. The hedge fund sold 795,332 shares, decreasing its position in the biotech company by 88% to just 108,411 shares.

Why it matters

Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders. The significant reduction in GSA Capital's position could signal concerns about the company's prospects or a shift in the hedge fund's investment strategy.

The details

In its 13F filing with the SEC, GSA Capital Partners reported owning 108,411 shares of Neumora Therapeutics as of the end of the third quarter, down from 903,743 shares held at the end of the previous quarter. This represents an 88% decrease in the hedge fund's position in the company.

  • GSA Capital Partners filed its 13F report for Q3 2026 on March 2, 2026.

The players

GSA Capital Partners LLP

A London-based hedge fund that invests in a variety of asset classes, including equities, fixed income, and alternative strategies.

Neumora Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in GSA Capital Partners' stake in Neumora Therapeutics could signal concerns about the company's future prospects or a shift in the hedge fund's investment strategy. Investors will likely be closely watching Neumora's progress as it continues to develop its pipeline of central nervous system treatments.